The purpose of the present study was to investigate whether 11 weeks of whole body vibration (WBV) training applied in a way that is commonly seen in practice, i.e. without additional loads, would improve muscle activation and/or contractile properties of the knee extensor muscles and counter movement jump height in healthy subjects. Ten subjects belonging to the experimental group trained three times a week and stood bare-foot with a 110 degrees knee angle on a vibration platform (30 Hz, 8 mm amplitude). They underwent five to eight sets of 1-min vibration with 1 min rest in between. Ten control subjects followed the same training programme but stood (110 degrees knee angle) beside the platform. Before, during and following the training period the subjects were tested. Values [mean (SEM)] obtained in the last test were expressed as percentages of the baseline value and presented for control and experimental groups. Quadriceps femoris isometric muscle force [105.4 (6.2)%, 99.9 (2.0)%; P=0.69], voluntary activation [107.1 (6.0)%, 101.1 (2.3)%; P=0.55] and maximal rate of voluntary force rise [95.4 (6.0)%, 103.3 (7.7)%; P=0.57] did not improve. The maximal rate of force rise during electrical stimulation was increased [102.3 (4.5)%, 123.6 (7.5)%; P=0.02]. Counter movement jump height was not affected by WBV [103.7 (1.8)%, 103.0 (2.8)%; P=0.71]. In conclusion, 11 weeks of standard two-legged WBV training without additional training loads did not improve functional knee extensor muscle strength in healthy young subjects.
The introduction of baked milk products in cow’s milk (CM) allergic children has previously been shown to accelerate induction tolerance in a selected group of children. However, there is no standardized baked milk product on the market. Recently, a new standardized, heated and glycated cow’s milk protein (HP) product was developed. The aim of this study was to measure safety and tolerability of a new, well characterized heated CM protein (HP) product in cow’s milk allergic (CMA) children between the age of 3 and 36 months. The children were recruited from seven clinics throughout the Netherlands. The HP product was introduced in six incremental doses under clinical supervision. Symptoms were registered after introduction of the HP product. Several questionnaires were filled out by parents of the children. Skin prick tests were performed with CM and HP product, sIgE to CM and α-lactalbumin (Bos d4), β-lactoglobulin (Bos d5), serum albumin (Bos d 6), lactoferrin (Bos d7) and casein (Bos d8). Whereas 72% percent (18 out of 25) of the children tolerated the HP product, seven children experienced adverse events. Risk factors for intolerance to the HP product were higher skin prick test (SPT) histamine equivalent index (HEP) results with CM and the HP product, higher specific IgE levels against Bos d4 and Bos d8 levels and Bos d5 levels. In conclusion, the HP product was tolerated by 72% of the CM allergic children. Outcomes of SPT with CM and the HP product, as well as values of sIgE against caseins, α-lactalbumin, and β-lactoglobulin may predict the tolerability of the HP product. Larger studies are needed to confirm these conclusions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.